Saturday 17 October 2026
Export TRIB’s income statement to Excel — free account
Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
8.03
0.10
+1.26%
Follow TRIB
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
92.42% | 90.93% | 69.76% | 55.26% | |
Piotroski F-Score |
1 | 2 | 4 | 4 | |
| (37.61%) | (36.64%) | (35.86%) | (32.70%) | ||
ROIC |
(25.55%) | (23.73%) | (16.99%) | (12.61%) | |
Return on Tangible Assets |
(630.54%) | (732.37%) | 37.37% | 30.75% | |
Average Days of Receivables |
80.47 | 108.88 | 95.70 | 81.54 | |
Free Cash Flow per Share |
(26.07) | (18.00) | (22.76) | (6.78) | |
Free Cash Flow |
(16.17) | (11.18) | (14.08) | (4.28) | |
Capital Expenditures |
(11.31) | (10.08) | (8.15) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(26.06%) | (18.19%) | (20.60%) | (6.76%) | |
Accounts Receivable Turnover |
3.48 | 2.72 | 3.18 | 4.46 | |
Accounts Payable Turnover |
1.32 | 1.10 | 0.95 | 1.02 | |
Inventory Turnover |
1.52 | 1.50 | 1.41 | 1.47 | |
Average Days of Payables |
295.61 | 360.86 | 403.06 | 385.95 | |
Days of Inventory on Hand |
224.66 | 227.75 | 255.49 | 236.11 | |
Tax Rate |
0.02 | 0.03 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
8.53% | 8.28% | 8.29% | 7.29% | |
Selling, General and Administrative Expense of Revenue |
63.72% | 64.01% | 66.06% | 57.87% | |
Share Based Compensation of Revenue |
1.24% | 0.88% | 0.74% | 0.44% | |
Interest Coverage |
(2.21) | (1.85) | (0.74) | (0.57) | |
Operating CF/Net income |
0.13 | 0.03 | 0.16 | 0.13 | |
Depreciation/Fixed assets |
0.54 | 0.59 | 0.51 | 0.54 | |
Capex/Depreciation |
(4.88) | (4.24) | (3.04) | (0.03) | |
Revenue per Share |
79.64 | 78.19 | 70.78 | 74.56 | |
Operating CF per Share |
(7.84) | (1.78) | (9.58) | (6.67) | |
Capex per Share |
(18.23) | (16.23) | (13.17) | (0.12) | |
Capex to Sales |
0.23 | 0.21 | 0.19 | 0.00 |
Columns are period end dates